Abstract 15941: Paired Single Cell Transcriptomics Reveals Immune Remodeling During PCSK9 Inhibition in Atherosclerotic Cardiovascular Disease
Background - Proprotein Convertase Subtilisin/Kexin Type 9 inhibitors (PCSK9i) lower LDL-C and reduce ASCVD events, but their effects on circulating immune composition and cell-specific transcriptional programs remain incompletely defined. Hypothesis: PCSK9 inhibition is associated with changes in monocyte tra...